RIGL vs. DAVE
RIGL (Rigel Pharmaceuticals, Inc.) and DAVE (Dave Inc.) are both stocks. RIGL operates in Biotechnology (Healthcare), while DAVE operates in Software - Application (Technology). Over the past 5 years, RIGL returned -3.96%/yr vs -2.05%/yr for DAVE. At a 0.19 correlation, their price movements are largely independent.
Performance
RIGL vs. DAVE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RIGL achieves a -23.30% return, which is significantly lower than DAVE's 29.52% return.
RIGL
- 1D
- 2.40%
- 1M
- 2.24%
- YTD
- -23.30%
- 6M
- -19.45%
- 1Y
- 54.23%
- 3Y*
- 27.10%
- 5Y*
- -3.96%
- 10Y*
- 3.28%
DAVE
- 1D
- 0.47%
- 1M
- 19.46%
- YTD
- 29.52%
- 6M
- 45.12%
- 1Y
- 20.37%
- 3Y*
- 269.82%
- 5Y*
- -2.05%
- 10Y*
- —
RIGL vs. DAVE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RIGL Rigel Pharmaceuticals, Inc. | -23.30% | 154.64% | 16.00% | -3.33% | -43.40% | -27.40% |
DAVE Dave Inc. | 29.52% | 154.73% | 936.61% | -9.64% | -97.17% | 4.59% |
Correlation
The correlation between RIGL and DAVE is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Apr 26, 2021 | 0.19 |
Fundamentals
RIGL:
$646.69M
DAVE:
$4.13B
RIGL:
$19.21
DAVE:
$15.54
RIGL:
1.71
DAVE:
18.45
RIGL:
0.00
DAVE:
0.08
RIGL:
2.08
DAVE:
7.53
RIGL:
1.62
DAVE:
20.26
RIGL:
$299.77M
DAVE:
$551.52M
RIGL:
$279.95M
DAVE:
$427.68M
RIGL:
$125.80M
DAVE:
$165.95M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RIGL vs. DAVE — Risk / Return Rank
RIGL
DAVE
RIGL vs. DAVE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and Dave Inc. (DAVE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RIGL | DAVE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.50 | ||
| Sortino ratioReturn per unit of downside risk | +0.75 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.11 | +0.09 |
| Calmar ratioReturn relative to maximum drawdown | 1.09 | 0.46 | +0.63 |
| Martin ratioReturn relative to average drawdown | 1.91 | 0.82 | +1.08 |
Loading charts...
Drawdowns
RIGL vs. DAVE - Drawdown Comparison
The maximum RIGL drawdown since its inception was -99.37%, roughly equal to the maximum DAVE drawdown of -99.01%. Use the drawdown chart below to compare losses from any high point for RIGL and DAVE.
Loading charts...
Drawdown Indicators
| RIGL | DAVE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.37% | -99.01% | -0.36% |
Max Drawdown (1Y)Largest decline over 1 year | -50.08% | -44.67% | -5.41% |
Max Drawdown (3Y)Largest decline over 3 years | -57.75% | -44.67% | -13.08% |
Max Drawdown (5Y)Largest decline over 5 years | -85.24% | -99.01% | +13.77% |
Max Drawdown (10Y)Largest decline over 10 years | -86.40% | — | — |
Current DrawdownCurrent decline from peak | -96.93% | -37.33% | -59.60% |
Average DrawdownAverage peak-to-trough decline | -90.91% | -68.91% | -22.00% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.64% | 24.93% | +3.71% |
Volatility
RIGL vs. DAVE - Volatility Comparison
The current volatility for Rigel Pharmaceuticals, Inc. (RIGL) is 12.05%, while Dave Inc. (DAVE) has a volatility of 18.61%. This indicates that RIGL experiences smaller price fluctuations and is considered to be less risky than DAVE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RIGL | DAVE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.05% | 18.61% | -6.56% |
Volatility (6M)Calculated over the trailing 6-month period | 36.64% | 48.97% | -12.33% |
Volatility (1Y)Calculated over the trailing 1-year period | 69.89% | 74.00% | -4.11% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.46% | 98.44% | -12.98% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 82.81% | 97.16% | -14.35% |
Dividends
RIGL vs. DAVE - Dividend Comparison
Neither RIGL nor DAVE has paid dividends to shareholders.
Financials
RIGL vs. DAVE - Financials Comparison
This section allows you to compare key financial metrics between Rigel Pharmaceuticals, Inc. and Dave Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RIGL vs. DAVE - Profitability Comparison
RIGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.
DAVE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Dave Inc. reported a gross profit of 120.00M and revenue of 147.59M. Therefore, the gross margin over that period was 81.3%.
RIGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.
DAVE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Dave Inc. reported an operating income of 21.15M and revenue of 147.59M, resulting in an operating margin of 14.3%.
RIGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.
DAVE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Dave Inc. reported a net income of 57.94M and revenue of 147.59M, resulting in a net margin of 39.3%.
Frequently Asked Questions
RIGL and DAVE have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DAVE has higher volatility (18.61%) compared to RIGL (12.05%). In terms of maximum drawdown, RIGL dropped -99.37% vs DAVE's -99.01%.
RIGL currently has the higher Sharpe Ratio (0.78 vs 0.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RIGL and DAVE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer